Graft-versus-host disease

(Redirected from Graft versus host disease)
Jump to: navigation, search

Graft-versus-host disease

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Graft-versus-host disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Graft-versus-host disease On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Graft-versus-host disease

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Graft-versus-host disease

CDC on Graft-versus-host disease

Graft-versus-host disease in the news

Blogs on Graft-versus-host disease

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Graft-versus-host disease

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and Keywords: GVHD

Overview

Graft-versus-host disease (GvHD) is a condition characterized by recipient tissue damage that arise from immunological activation of donor T lymphocytes. It typically occurs in the setting of bone marrow transplantation. Donor T cells mount a response against foreign host cells in the gastrointestinal system, liver, and skin.

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Graft-versus-host disease from Other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | Chest X Ray | CT | Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical Therapy Ruxolitinib has been used for GvHD that is refractory to steroids.[1]

| Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case #1

Related Chapters

  • Assouan D, Lebon D, Charbonnier A, Royer B, Marolleau JP, Gruson B (2017). "Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus-host disease.". Br J Haematol. PMID 28444730. doi:10.1111/bjh.14679. 

  • Linked-in.jpg